Published in J Virol on September 01, 1982
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 6.32
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A (1984) 5.27
Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci U S A (1986) 5.12
Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog (2006) 4.80
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 4.05
Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells. Proc Natl Acad Sci U S A (1987) 3.98
A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growth-transformed lymphocytes. J Virol (1987) 3.58
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol (1990) 3.54
Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells. J Virol (1987) 3.53
Epstein-Barr virus with heterogeneous DNA disrupts latency. J Virol (1984) 3.51
Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24
Spliced RNA from the IR1-U2 region of Epstein-Barr virus: presence of an open reading frame for a repetitive polypeptide. EMBO J (1984) 3.12
Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J (1986) 3.07
Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus. J Virol (1989) 2.86
EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus. J Virol (1991) 2.70
Transformation by Epstein-Barr virus requires DNA sequences in the region of BamHI fragments Y and H. J Virol (1985) 2.56
Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells. J Virol (1986) 2.28
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23
Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol (1992) 2.14
RNA encoded by the IR1-U2 region of Epstein-Barr virus DNA in latently infected, growth-transformed cells. J Virol (1983) 2.12
The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus. EMBO J (1984) 2.00
Epstein-Barr virus recombinants from overlapping cosmid fragments. J Virol (1993) 1.97
The Epstein-Barr virus immediate-early gene product, BMLF1, acts in trans by a posttranscriptional mechanism which is reporter gene dependent. J Virol (1989) 1.86
Identification and nucleotide sequences of two similar tandem direct repeats in Epstein-Barr virus DNA. J Virol (1982) 1.73
Host cell and EBNA-2 regulation of Epstein-Barr virus latent-cycle promoter activity in B lymphocytes. J Virol (1992) 1.55
Palindromic structure and polypeptide expression of 36 kilobase pairs of heterogeneous Epstein-Barr virus (P3HR-1) DNA. J Virol (1986) 1.41
Identification and expression of a nuclear antigen from the genomic region of the Jijoye strain of Epstein-Barr virus that is missing in its nonimmortalizing deletion mutant, P3HR-1. Proc Natl Acad Sci U S A (1985) 1.38
Isolation and characterization of cDNA clones corresponding to transcripts from the BamHI H and F regions of the Epstein-Barr virus genome. J Virol (1987) 1.34
Two families of sequences in the small RNA-encoding region of Epstein-Barr virus (EBV) correlate with EBV types A and B. J Virol (1989) 1.34
Reducing the complexity of the transforming Epstein-Barr virus genome to 64 kilobase pairs. J Virol (1995) 1.14
Epstein-Barr virus induction of recombinase-activating genes RAG1 and RAG2. J Virol (1995) 1.05
Construction and use of cDNA clones for the mapping and identification of Epstein-Barr virus early P3HR-1 mRNAs. J Virol (1985) 1.04
A selectable marker allows investigation of a nontransforming Epstein-Barr virus mutant. J Virol (1992) 0.95
No evidence for differences in the Epstein-Barr virus genome carried in Burkitt lymphoma cells and nonmalignant lymphoblastoid cells from the same patients. Proc Natl Acad Sci U S A (1984) 0.92
Autoantigenic proteins that bind recombinogenic sequences in Epstein-Barr virus and cellular DNA. Proc Natl Acad Sci U S A (1994) 0.87
An Epstein-Barr virus isolated from a lymphoblastoid cell line has a 16-kilobase-pair deletion which includes gp350 and the Epstein-Barr virus nuclear antigen 3A. J Virol (2001) 0.85
The Role of Gammaherpesviruses in Cancer Pathogenesis. Pathogens (2016) 0.83
Amplification of Epstein-Barr virus (EBV) DNA by superinfection with a strain of EBV derived from nasopharyngeal carcinoma. J Virol (1988) 0.81
Distinctive effects of the Epstein-Barr virus family of repeats on viral latent gene promoter activity and B-lymphocyte transformation. J Virol (2009) 0.81
Points of recombination in Epstein-Barr virus (EBV) strain P3HR-1-derived heterogeneous DNA as indexes to EBV DNA recombinogenic events in vivo. J Virol (2008) 0.76
Epithelial cell retention of transcriptionally active, P3HR-1-derived heterogeneous Epstein-Barr virus DNA with concurrent loss of parental virus. J Virol (2011) 0.75
Human neonatal lymphocytes immortalized after microinjection of Epstein-Barr virus DNA. J Virol (1987) 0.75
Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol (1975) 503.08
Sequencing end-labeled DNA with base-specific chemical cleavages. Methods Enzymol (1980) 287.68
Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I. J Mol Biol (1977) 205.11
A simple method for DNA restriction site mapping. Nucleic Acids Res (1976) 22.24
Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer (1973) 14.90
The nucleotide sequence of bacteriophage phiX174. J Mol Biol (1978) 13.55
Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line. J Virol (1967) 8.29
Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science (1970) 7.60
Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. J Virol (1980) 5.59
Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference. Proc Natl Acad Sci U S A (1974) 5.54
Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A (1980) 5.02
Epstein-Barr virus RNA VII: size and direction of transcription of virus-specified cytoplasmic RNAs in a transformed cell line. Proc Natl Acad Sci U S A (1981) 4.77
New Epstein-Barr virus variants from cellular subclones of P3J-HR-1 Burkitt lymphoma. Nature (1982) 4.43
Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol (1981) 4.38
DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative. Cell (1980) 4.14
An improved procedure for utilizing terminal transferase to add homopolymers to the 3' termini of DNA. Nucleic Acids Res (1981) 3.53
A comprehensive molecular map of bacteriophage lambda. Gene (1979) 3.46
DNA of Epstein-Barr virus. IV. Linkage map of restriction enzyme fragments of the B95-8 and W91 strains of Epstein-Barr Virus. J Virol (1978) 3.41
DNA of Epstein-Barr virus. I. Comparative studies of the DNA of Epstein-Barr virus from HR-1 and B95-8 cells: size, structure, and relatedness. J Virol (1975) 3.13
Comparison of Epstein-Barr virus strains of different origin by analysis of the viral DNAs. J Virol (1980) 3.00
Epstein-Barr virus-specific RNA. III. Mapping of DNA encoding viral RNA in restringent infection. J Virol (1979) 2.90
Enemies within: the genesis of retrovirus oncogenes. Cell (1981) 2.86
DNA of Epstein-Barr virus. III. Identification of restriction enzyme fragments that contain DNA sequences which differ among strains of Epstein-Barr virus. J Virol (1978) 2.76
The structure of the termini of the DNA of Epstein-Barr virus. Cell (1979) 2.69
DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA. J Virol (1979) 2.63
Epstein-Barr virus RNA. VI. Viral RNA in restringently and abortively infected Raji cells. J Virol (1981) 2.26
Biological properties and viral surface antigens of Burkitt lymphoma- and mononucleosis- derived strains of Epstein-Barr virus released from transformed marmoset cells. J Virol (1976) 2.22
DNA of Epstein-Barr virus. VI. Mapping of the internal tandem reiteration. J Virol (1979) 2.10
NC37-R1 Epstein-Barr virus (EBV): a possible recombinant between intracellular NC37 viral DNA and superinfecting P3HR-1 EBV. Intervirology (1980) 1.92
A new tumour-derived transforming strain of Epstein-Barr virus. Nature (1978) 1.84
Induction and biological characterization of the Epstein-Barr virus (EBV) carried by the Jijoye lymphoma line. Virology (1980) 1.55
Herpesvirus papio DNA is similar in organization to Epstein-Barr virus DNA. J Virol (1981) 1.54
Colinearity between the DNAs of Epstein-Barr virus and herpesvirus papio. J Virol (1981) 1.47
Properties of a baboon lymphotropic herpesvirus related to Epstein-Barr virus. Int J Cancer (1976) 1.37
Antigens and DNA of a chimpanzee agent related to Epstein-Barr virus. J Virol (1976) 1.37
DNA of herpesvirus pan, a third member of the Epstein-Barr virus-Herpesvirus papio group. J Virol (1982) 1.24
Epstein-Barr virus DNA. X. Direct repeat within the internal direct repeat of Epstein-Barr virus DNA. J Virol (1981) 1.20
Collinear relationships of herpesvirus papio DNA to Epstein--Barr virus DNA. Virology (1981) 0.98
An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell (1985) 10.13
Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell (1991) 7.40
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc Natl Acad Sci U S A (1989) 6.32
Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol (1990) 6.23
The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell (1995) 5.97
Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A (1993) 5.92
Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol (1984) 5.87
Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A (1987) 5.68
A membrane protein encoded by Epstein-Barr virus in latent growth-transforming infection. Proc Natl Acad Sci U S A (1984) 5.60
Epstein-Barr virus RNA. V. Viral RNA in a restringently infected, growth-transformed cell line. J Virol (1980) 5.59
Hip contact forces and gait patterns from routine activities. J Biomech (2001) 5.33
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2. Proc Natl Acad Sci U S A (1984) 5.27
Nucleotide sequences of mRNAs encoding Epstein-Barr virus nuclear proteins: a probable transcriptional initiation site. Proc Natl Acad Sci U S A (1986) 5.12
Genetic relatedness of type 1 and type 2 herpes simplex viruses. J Virol (1972) 5.11
Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping. Proc Natl Acad Sci U S A (1980) 5.02
One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain. Proc Natl Acad Sci U S A (1983) 4.94
Epstein-Barr virus RNA VII: size and direction of transcription of virus-specified cytoplasmic RNAs in a transformed cell line. Proc Natl Acad Sci U S A (1981) 4.77
Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol (1988) 4.55
Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells. J Virol (1981) 4.38
Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol (1990) 4.24
DNA of Epstein-Barr virus VIII: B95-8, the previous prototype, is an unusual deletion derivative. Cell (1980) 4.14
Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med (1992) 4.11
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 4.05
Simple repeat array in Epstein-Barr virus DNA encodes part of the Epstein-Barr nuclear antigen. Science (1983) 4.04
The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein. Proc Natl Acad Sci U S A (1994) 3.88
Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell (1987) 3.87
Proteins of Epstein-Barr virus. I. Analysis of the polypeptides of purified enveloped Epstein-Barr virus. J Virol (1976) 3.83
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med (1992) 3.75
Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. J Virol (1986) 3.65
Early events in Epstein-Barr virus infection of human B lymphocytes. Virology (1991) 3.60
A bicistronic Epstein-Barr virus mRNA encodes two nuclear proteins in latently infected, growth-transformed lymphocytes. J Virol (1987) 3.58
Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol (1990) 3.54
DNA of Epstein-Barr virus. IV. Linkage map of restriction enzyme fragments of the B95-8 and W91 strains of Epstein-Barr Virus. J Virol (1978) 3.41
Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med (1989) 3.32
Monoclonal antibodies to the latent membrane protein of Epstein-Barr virus reveal heterogeneity of the protein and inducible expression in virus-transformed cells. J Gen Virol (1987) 3.28
Epstein-Barr virus RNA. VIII. Viral RNA in permissively infected B95-8 cells. J Virol (1982) 3.26
A second nuclear protein is encoded by Epstein-Barr virus in latent infection. Science (1985) 3.26
Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation. J Virol (1991) 3.24
Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol (1996) 3.22
Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. J Virol (1993) 3.19
Recombinant Epstein-Barr virus with small RNA (EBER) genes deleted transforms lymphocytes and replicates in vitro. Proc Natl Acad Sci U S A (1991) 3.17
Calmodulin-dependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Natl Acad Sci U S A (1991) 3.15
Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol (1989) 3.09
Interventions for promoting booster seat use in four to eight year olds traveling in motor vehicles. Cochrane Database Syst Rev (2006) 3.07
An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum (2000) 3.06
Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies. J Virol (1983) 3.06
Myoblast transfer in the treatment of Duchenne's muscular dystrophy. N Engl J Med (1995) 2.96
Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription. J Biol Chem (1997) 2.93
Epstein-Barr virus-specific RNA. III. Mapping of DNA encoding viral RNA in restringent infection. J Virol (1979) 2.90
Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem (1996) 2.85
The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol (1991) 2.81
Persistence of the entire Epstein-Barr virus genome integrated into human lymphocyte DNA. Science (1984) 2.77
DNA of Epstein-Barr virus. III. Identification of restriction enzyme fragments that contain DNA sequences which differ among strains of Epstein-Barr virus. J Virol (1978) 2.76
Gene targeting of BPAG1: abnormalities in mechanical strength and cell migration in stratified epithelia and neurologic degeneration. Cell (1995) 2.75
The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. J Virol (1988) 2.74
Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity (1995) 2.74
Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol (1995) 2.71
DNA of Epstein-Barr virus. V. Direct repeats of the ends of Epstein-Barr virus DNA. J Virol (1979) 2.63
Definitive identification of a member of the Epstein-Barr virus nuclear protein 3 family. Proc Natl Acad Sci U S A (1986) 2.62
Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc Natl Acad Sci U S A (1991) 2.61
Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. Proc Natl Acad Sci U S A (1983) 2.61
A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J Virol (1990) 2.60
Limited diversity of the rearranged T-cell gamma gene. Nature (1985) 2.58
Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex. Virology (1987) 2.53
Simple repeat sequence in Epstein-Barr virus DNA is transcribed in latent and productive infections. J Virol (1982) 2.51
NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A (2000) 2.48
Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell (1994) 2.48
Dominant selection of an invariant T cell antigen receptor in response to persistent infection by Epstein-Barr virus. J Exp Med (1994) 2.47
Epstein-barr virus-specific RNA. II. Analysis of polyadenylated viral RNA in restringent, abortive, and prooductive infections. J Virol (1977) 2.38
An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A (1994) 2.38
Long internal direct repeat in Epstein-Barr virus DNA. J Virol (1982) 2.36
The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol Cell Biol (1995) 2.36
A novel interleukin-12 p40-related protein induced by latent Epstein-Barr virus infection in B lymphocytes. J Virol (1996) 2.34
BHRF1, the Epstein-Barr virus gene with homology to Bc12, is dispensable for B-lymphocyte transformation and virus replication. J Virol (1991) 2.28
Expression of the Epstein-Barr virus nuclear protein 2 in rodent cells. J Virol (1986) 2.28
Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element. J Virol (1991) 2.28
A fifth Epstein-Barr virus nuclear protein (EBNA3C) is expressed in latently infected growth-transformed lymphocytes. J Virol (1988) 2.27
Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. Proc Natl Acad Sci U S A (2001) 2.26
Epstein-Barr virus RNA. VI. Viral RNA in restringently and abortively infected Raji cells. J Virol (1981) 2.26
Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol (1995) 2.25
The structural basis for the recognition of diverse receptor sequences by TRAF2. Mol Cell (1999) 2.25
An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator. J Virol (1991) 2.24
Distinction between Epstein-Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol (1989) 2.23